Clinical Trial Update: Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating continuous infusion of first-generation 5-HT3 receptor antagonists with dexamethasone in pediatric cancer; study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• First-generation 5-HT3 receptor antagonists (continuous infusion)

Snippet

Sponsor: Immune Oncology Research Institute | Conditions: Pediatric Cancer | Phase 3 | Status: COMPLETED